Prevest Denpro Ltd
Prevest Denpro Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
The company posted a 13% sales growth in FY 2025, surpassing the global dental market growth forecast of 6-8%. - They aim for higher growth in coming years by expanding diversified product lines like oral care products, 3D printers, and 3D resins. - The growth is driven by strengthening domestic market focus while maintaining export and international presence. - Efforts to penetrate rural markets and metro areas are ongoing, with improved dealer/distributor appointments. - Launch of new products like 3D printers is planned aggressively in the current year to boost revenue. - The U.S. The company reported a 13.6% revenue growth for FY 2024-25, with EBITDA margins steady around 39% and PAT growth of 12.5%, signaling stable profitability.
From Prevest Denpro Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company posted a 13% sales growth in FY 2025, surpassing the global dental market growth forecast of 6-8%.
- They aim for higher growth in coming years by expanding diversified product lines like oral care products, 3D printers, and 3D resins.
- The growth is driven by strengthening domestic market focus while maintaining export and international presence.
- Efforts to penetrate rural markets and metro areas are ongoing, with improved dealer/distributor appointments.
- Launch of new products like 3D printers is planned aggressively in the current year to boost revenue.
- The U.S. subsidiary is expected to contribute as private labeling and contract manufacturing opportunities grow.
2 more points from Prevest Denpro Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Prevest Denpro Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is heavily investing in R&D to develop new, innovative dental products, including digital dentistry solutions such as advanced 3D printers and scanners.
- A new state-of-the-art R&D center has been set up, recognized by the Ministry of Science and Technology.
- Strategic investment in building the digital dentistry portfolio is a key focus, seeing it as the future growth driver.
- Incorporation of Axiodent Inc. in the U.S. to strengthen market presence and enable private labeling and local product positioning.
- Continued investments in operational excellence with lean manufacturing, ERP upgrades, and supply chain optimization for sustainable growth.
- Private labeling is being pursued actively as a business opportunity to add revenue streams.
2 more points from Prevest Denpro Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Prevest Denpro Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Prevest Denpro Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Prevest Denpro Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹19 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Prevest Denpro's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Vaidya Sane (Q4 FY25)
120 crores. Key concall takeaways from Vaidya Sane Ayurved Laboratories Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Poly Medicure Ltd (Q4 FY25)
EBITDA margins guided between 25%-27%, with potential upside if export growth exceeds 15%. Key concall takeaways from Poly Medicure Ltd's Q4 FY25 earnings call…
- OSEL Devices (Q4 FY25)
Current order-in-hand for OSEL Devices Limited is approximately INR 40-45 crores. Key concall takeaways from OSEL Devices Ltd's Q4 FY25 earnings call — and how…
- Aprameya Enginee (Q4 FY25)
Current order book: Approximately INR 60 crores. Key concall takeaways from Aprameya Engineering Ltd's Q4 FY25 earnings call — and how it ranks against sector…
Arthneeti Pro · Annual
Prevest Denpro Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Prevest Denpro Ltd Q4 FY25 results?
The company posted a 13% sales growth in FY 2025, surpassing the global dental market growth forecast of 6-8%. - They aim for higher growth in coming years by expanding diversified product lines like oral care products, 3D printers, and 3D resins. - The growth is driven by strengthening domestic market focus while maintaining export and international presence. - Efforts to penetrate rural markets and metro areas are ongoing, with improved dealer/distributor appointments. - Launch of new products like 3D printers is planned aggressively in the current year to boost revenue. - The U.S. The company reported a 13.6% revenue growth for FY 2024-25, with EBITDA margins steady around 39% and PAT growth of 12.5%, signaling stable profitability.
What is Prevest Denpro Ltd share price analysis?
Prevest Denpro Ltd currently shows a neutral. The stock trades at a P/E of 21.4 with a market cap of ₹458 Cr. Investors should review the full earnings analysis for detailed insights.
Is Prevest Denpro Ltd planning capital expenditure?
The company is heavily investing in R&D to develop new, innovative dental products, including digital dentistry solutions such as advanced 3D printers and scanners. - A new state-of-the-art R&D center has been set up, recognized by the Ministry of Science and Technology. - Strategic investment in building the digital dentistry portfolio is a key focus, seeing it as the future growth driver. - Incorporation of Axiodent Inc.
Keep Prevest Denpro Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.